Taku Kobayashi
0000-0002-2073-4234
Kitasato University
6 papers found
Refreshing results…
Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study
iSTART-II: An Update on the i Support Therapy–Access to Rapid Treatment (iSTART) Approach for Patient-Centered Therapy in Mild-to-Moderate Ulcerative Colitis
International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease
Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis
Mechanism-Based Treatment Strategies for IBD: Cytokines, Cell Adhesion Molecules, JAK Inhibitors, Gut Flora, and More
Th17 plasticity and its relevance to inflammatory bowel disease
Missing publications? Search for publications with a matching author name.